Ernexa Therapeutics (NASDAQ:ERNA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Ernexa Therapeutics (NASDAQ:ERNA) to a hold rating in a research note issued to investors on Saturday morning.

ERNA has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Brookline Capital Markets initiated coverage on shares of Ernexa Therapeutics in a research report on Thursday. They set a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Trading Down 3.7%

Shares of ERNA opened at $7.53 on Friday. The firm has a market cap of $8.78 million, a PE ratio of -0.10 and a beta of 1.88. The firm has a fifty day simple moving average of $5.89 and a two-hundred day simple moving average of $21.13. Ernexa Therapeutics has a 1-year low of $3.18 and a 1-year high of $100.46.

Institutional Investors Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Institutional investors own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.